BiotechTube
MonTa Biosciences

MonTa Biosciences

Copenhagen, Denmark· Est.
montabiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

MonTa Biosciences is advancing MBS8, a second-generation systemic Toll-like receptor 7 (TLR7) agonist, as a potential best-in-class asset for cancer immunotherapy. The company has completed a Phase I safety study, established a recommended dose, and initiated an expansion study in checkpoint-resistant melanoma in Denmark and Spain. MonTa's technology is designed to turn immunologically 'cold' tumors 'hot' and restore responsiveness to PD-1 inhibitors, positioning it in a TLR7 field with strong clinical validation and investor interest.

Oncology

Technology Platform

Second-generation systemic TLR7 agonist platform designed for improved efficacy and safety via intravenous infusion to activate innate immunity and overcome checkpoint inhibitor resistance.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The large and growing population of cancer patients resistant to checkpoint inhibitors represents a major unmet need.
Strong recent clinical validation for the TLR7 agonist class, including a Nature publication showing near-doubling of survival in combination, creates significant investor and partner interest in the field.

Risk Factors

Key risks include clinical failure of MBS8 in ongoing expansion studies, particularly regarding efficacy or safety in a broader patient population.
The company also faces intense competition in the TLR7 space and, as a small private firm, relies heavily on future fundraising or a partnership for survival and commercialization.

Competitive Landscape

MonTa competes in the TLR7 agonist space, which includes both intra-tumoral and systemic agents from companies like Merck, Gilead (via acquisitions), and other biotechs. Its strategy is to differentiate MBS8 as a superior systemic agent with an optimized safety and efficacy profile for combination with checkpoint inhibitors.

More companies in Small Molecule Drugs →More companies in Denmark →